Carbapenemase type-dependent pharmacodynamic activity of minocycline–biapenem combination against carbapenemase-producing Klebsiella pneumoniae
JAC-Antimicrobial Resistance · 02.07.2026 · 8 (4)
DOI: 10.1093/jacamr/dlag168 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 06.08.2026. Verfasst von Takashi Okanda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Objectives
The activity of antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae (CPKP) is likely to depend on the underlying resistance mechanism; however, this has not been systematically evaluated. We assessed the in vitro activity of minocycline in combination with biapenem across major carbapenemase types.
Methods
A total of 79 clinical CPKP isolates from Japan (n = 30) and Bangladesh (n = 49), including New Delhi metallo-β-lactamase (NDM) (n = 40), imipenemase (IMP) (n = 10), K. pneumoniae carbapenemase (KPC) (n = 10), oxacillinase-48-like (OXA-48-like) (n = 16) and NDM+OXA-48-like (n = 3), were analysed. MICs were determined by broth microdilution in accordance with CLSI guidelines. Combination activity was evaluated using checkerboard assays to calculate fractional inhibitory concentration indices (FICIs), and cumulative growth inhibition was analysed across concentration matrices.
Results
Single-agent MIC90 values of minocycline were 32, 16, 8, 32 and 32 mg/L for NDM, IMP, KPC, OXA-48-like and NDM+OXA-48-like isolates, respectively; corresponding biapenem MIC90 values were 32, 2, 256, 8 and 256 mg/L. Synergistic interactions (FICI ≤0.5) with the minocycline–biapenem combination were observed against 98% of NDM, 80% of IMP, 60% of KPC, 38% of OXA-48-like and 100% of NDM+OXA-48-like isolates. At minocycline 4 mg/L plus biapenem 1 mg/L, inhibition rates were 98%, 100%, 80% and 63% for NDM, IMP, KPC and OXA-48-like isolates, respectively.
Conclusions
The activity of the minocycline–biapenem combination differs substantially according to carbapenemase type. These findings indicate that combination efficacy is not predictable from single-agent susceptibility alone and highlight the importance of pharmacodynamic evaluation when optimizing treatment strategies for CPKP.
Autor:innen und Institutionen
- Department of Microbiology, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan.
- Department of Clinical Laboratory Technology, St. Marianna University Hospital, Kawasaki, Kanagawa, Japan.
- Department of Infectious Diseases, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
ORCID-Profile: Takashi Okanda
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Okanda, T., Nakajima, N., Yamaguchi, T., Koshikawa, T., Oyanagi, T., Takano, T., Kunishima, H., Kaku, M., & Takemura, H. (2026). Carbapenemase type-dependent pharmacodynamic activity of minocycline–biapenem combination against carbapenemase-producing Klebsiella pneumoniae. JAC-Antimicrobial Resistance, 8(4). https://doi.org/10.1093/jacamr/dlag168
Vancouver
Okanda T, Nakajima N, Yamaguchi T, Koshikawa T, Oyanagi T, Takano T, et al. Carbapenemase type-dependent pharmacodynamic activity of minocycline–biapenem combination against carbapenemase-producing Klebsiella pneumoniae. JAC-Antimicrobial Resistance. 2026;8(4). doi:10.1093/jacamr/dlag168
BibTeX
@article{Okanda2026,
author = {Okanda, Takashi and Nakajima, Niinyo and Yamaguchi, Tetsuo and Koshikawa, Takuro and Oyanagi, Tadatomo and Takano, Tomonori and Kunishima, Hiroyuki and Kaku, Mitsuo and Takemura, Hiromu},
title = {Carbapenemase type-dependent pharmacodynamic activity of minocycline–biapenem combination against carbapenemase-producing Klebsiella pneumoniae},
journal = {JAC-Antimicrobial Resistance},
year = {2026},
volume = {8},
number = {4},
doi = {10.1093/jacamr/dlag168}
}
EUVIMED